Orthotopic Liver Transplantation in Human-Immunodeficiency-Virus-Positive Patients in Germany

Table 5

Recurrence of hepatitis C in HIV-infected patients and outcome after OLT.

Viral hepatitis	HCV genotype	HCV therapy	Nonresponse	Survival, followup (months)
HCV	2a/2c	IFN/RBV/amantadine	SVR	Living, 114
HCV	3a	IFN/RBV	SVR	Death, 93
HCV	1a	IFN/RBV/amantadine	EVR/SVR	Living, 89
HCV	1a	IFN/RBV/amantadine	EVR/SVR	Living, 82
HCV	1a	IFN/RBV	SVR	Living, 66
HCV/HBV/HDV	1a	IFN/RBV	Nonresponse	Death, 56
HCV	1a/b	IFN/RBV	Nonresponse	Death, 8
HCV	n.a.	No	/	Death, 31
HCV	3a	No	/	Death, 25
HCV	n.a.	No	/	Death, 13
HCV	n.a.	No	/	Death, 10
HCV	1a	No	/	Death, 3
HCV	n.a.	No	/	Death, 2
HCV	n.a.	No	/	Death,1
HCV	n.a.	No	/	Living, 74
HCV	1b	n.a.	n.a.	Living, 32
HCV	1b	n.a.	n.a.	Living, 67
HCV	3a	No	/	Living, 39
HCV/HBV	1	No	/	Living, 18
HCV	1a	No	/	Living, 44
HCV	n.a.	No	Spontaneous viral clearance	Living, 54

IFN: interferon, RBV: ribavirin, EVR: early virological response, SVR: sustained virological response, HCV: hepatitis C virus, HBV: hepatitis B virus, HDV: hepatitis D virus.